Kingmed (603882.SS): 1H26 prelim NP beat; Launching new equity incentive plan; Buy

Research evidence excerpt

Kingmed (603882.SS): 1H26 prelim NP beat; Launching new equity incentive plan; Buy

Goldman Sachs Kingmed (603882.SS)

Disclosure Appendix

Reg AC

We, Tianyi Yan and Michael Zheng, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject

company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the

specific recommendations or views expressed in this report.

Contributing Authors: Tianyi Yan Goldman Sachs (China) Securities Company Limited, Ziyi Chen Goldman Sachs (Asia) L.L.C., Michael Zheng Goldman

Sachs (China) Securities Company Limited.

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs’ Global Investment

Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks)

and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth,

Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The

normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may

vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock’s forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a

higher percentile indicating a higher growth company.